Characteristics and Changes of Pediatric Therapeutic Trials under the Best Pharmaceuticals for Children Act.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Journal of child health care : for professionals working with children in the hospital and community · 2022
   Trial
2. Dexmedetomidine use in Infants undergoing Cooling due to neonatal Encephalopathy (DICE trial): safety and pharmacokinetics.Pediatric research · 2026
   Article
3. A Review of Trials for Unsuccessful Pediatric Drug Development Programs Submitted to the US Food and Drug Administration 2015-2022.Therapeutic innovation & regulatory science · 2026
   Review
4. Describing Inconsistencies in Pediatric Labeling of Medical Devices.JAMA network open · 2025
   Article
5. State of the art in pediatric nanomedicines.Drug delivery and translational research · 2024
   Review
6. Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress.Cold Spring Harbor perspectives in medicine · 2024
   Review
7. Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.Clinical trials (London, England) · 2021
   Article
8. Prescribing drugs to overweight and obese children: Balancing efficacy and safety.Paediatrics & child health · 2021
   Review
9. Exploration and Ethical Analysis of Open-label Pediatric Vaccine Trials in a Pandemic.Clinical therapeutics · 2021
   Article
10. Racial and Ethnic Diversity in Studies Funded Under the Best Pharmaceuticals for Children Act.Pediatrics · 2021
    Article
11. Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial): A Randomized Controlled Trial: Background, Aims and Study Protocol.Frontiers in pain research (Lausanne, Switzerland) · 2021
    Article
12. Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Article
13. Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review.Drugs - real world outcomes · 2020
    Review
14. Developing a pediatric pain data repository.JAMIA open · 2020
    Article
15. The best pharmaceuticals for children-what can we do?Translational pediatrics · 2020
    Article
16. Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities.Paediatric drugs · 2020
    Review
17. Assessing Drug Safety in Children - The Role of Real-World Data.The New England journal of medicine · 2018
    Article
18. Pharmacokinetics of nanotechnology-based formulations in pediatric populations.Advanced drug delivery reviews
    Review

Corrections and comments

• Comment on
  The Need for Pediatric Drug Development.2018

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as